Introduction
DNA-liposome complexes in vivo. This strategy is It has been suggested that most malignancies have designed to induce an immune response to syngeneic evolved mechanisms to evade immune detection, but the tumor cells, initially directed to the allogeneic MHC class ability to induce an immune response against tumors has I gene (HLA-B7 for humans or H-2K s for mice), consebeen demonstrated after immunologic activation, and the quently generating tumor-specific immune responses. 20 stimulation of specific antitumor immune recognition Alternative genetic targets may also be candidates to offers the potential to provide therapy for malignancy. A limit tumor growth after gene transfer in vivo. Among variety of approaches for inducing immune recognition these approaches, genes which affect cell cycle proof tumors or increasing the strength of the immune gression, specific cyclin/cyclin-dependent kinase inhibiresponse have been studied. Among the methods tors (CKIs), have shown antitumor effects in animal moddeveloped to elicit immune rejection are the stimulation els. 21 Expression of the p21 CKI using gene transfer of major histocompatibility-restricted lysis through a techniques suppressed the growth of malignant cells in cytotoxic T cell (CTL) response, 1 tumor infiltrating lymvitro and in vivo. 21 In the previous study, the arrest of cell phocytes, [2] [3] [4] immunization with tumor cells, 5 adminiscycle progression was due to growth arrest associated tration of cytokines 6 or tumor-associated antigen sensiwith terminal differentiation. In this report, we have tized lymphoid cells, [6] [7] [8] natural killer cells, 9, 10 and tested the efficacy of gene transfer of the murine MHC macrophages. Others have attempted to introduce new gene, H-2K b , in combination with the gene for p21, using antigens into tumor cells by treatment with drugs or adenoviral vectors in vivo. We sought to determine virus infection. [11] [12] [13] Furthermore, the expression of cytowhether combination gene transfer with an immunomodkine genes by genetic modification of tumor cells has ulatory and antiproliferative gene could potentiate the been shown to induce an antitumor response, mediated antitumor immune response. by lymphocytes or other inflammatory cells.
14-18
We have previously developed a gene transfer protocol which utilizes the human MHC class I molecule, HLAResults B7, for human trials, 19 or a murine gene product, H-2K s , in mouse studies, 20 Renca cells (p21). 15 When Renca cells were infected with 
Discussion
In this study, we have examined the efficacy of combination gene therapy for the treatment of tumors established in mice in vivo. We used two genes which exert effects through distinct mechanisms to prevent minal differentiation. 21 Both genes were incorporated The percentage of mice which remained tumor-free 44 days after inoculation with 10 6 Renca cells and treatment with the indicated vectors as described in Materials and methods is shown. Each group included eight mice, except for ADV-p21 (n = 7).
Figure 4 Measurement of CTL activity against H-2K b molecules of tumor-bearing mice with various treatments. Splenic lymphocytes prepared from each group (3 × 10 7 cells) were stimulated with 6 × 10 5 irradiated C57BL6 splenic lymphocytes and 20 U/ml recombinant human IL-2 for 5 days in vitro. Stimulated lymphocytes derived from mice whose tumors were injected with ADV-⌬E1 (a), ADV-p21(b), ADV-K b (c), or ADV-K b and ADVp21 (d) were used for CTL assays in each E:T ratio. Cr 51 labeled Renca cells () and Renca-K b cells (í) were used as target cells. Specific lysis was calculated using the following formula: specific lysis (%) = (experimental release (c.p.m.) − spontaneous release (c.p.m.))/(maximum release (c.p.m.) − spontaneous release (c.p.m.)).
into adenoviral vectors and transferred alone, or in commice were found in the groups infused with ADV-p21 or with the combination of ADV-K b and ADV-p21 adenobination, directly into tumor tissues. As reported previously, the introduction of the p21 gene alone into tumor virus. The proportion of mice available for evaluation in each group which became tumor-free was 42.9% and tissues showed a reduction in tumor size in vivo. 21 Similar to results using other foreign class I MHC genes with 62.5%, respectively after 44 days. The existence of tumorfree mice in the ADV-⌬E1 treated group (12.5%) suggests different vectors, H-2K b gene transfer alone also inhibited tumor growth. We demonstrated here that the combia background effect of the adenoviral vector for the rejection of tumor. In fact, we observed some toxic effects nation therapy using recombinant adenoviruses encoding the H-2K b and p21 gene respectively can reduce the with the infection of adenovirus on Renca cells in vivo ( Figure 2 ) and in vitro (data not shown). However, treatgrowth of tumor cells and eliminate tumor tissues more effectively than the introduction of either gene alone ment with ADV-K b and ADV-p21 together resulted in a trend towards an increased rate of rejection of tumor (Figure 3) . Importantly, increased numbers of tumor-free cells, and the combination therapy provided the highest (DMEM; Gibco, Grand Island, NY, USA), supplemented with 10% fetal calf serum (FCS; Gibco). A stable transfectfrequency for generating tumor-free mice.
Cytotoxic T cell assays provided evidence that the ant of the Renca cells which expresses the H-2K b molecule was established by co-transfection with RSV-neo induction of an immune response against H-2K b occurred in ADV-K b and ADV-K b plus ADV-p21 treated mice in and RSV-K b expression vectors. The expression of the H-2K b gene on RSV-K b was driven by the Rous sarcoma vivo, supporting the observation that tumor rejection in the groups treated with ADV-K b is mainly dependent on virus enhancer and the promoter, and the transcription was terminated by the SV40 large T antigen polyadenylthe host defense mechanism which recognizes and removes tumors modified with an allogeneic MHC class ation signal sequence. I gene. When the parental Renca cell was used as a target cell line in this study, no CTL response against parental Preparation of recombinant adenovirus The recombinant adenoviral vectors, ADV-K b and ADVcells was detected. This finding suggests that a specific anti-H-2K b response was induced in cytotoxic T lymphop21, were constructed by homologous recombination between sub360 genomic DNA, an Ad5 derivative with cytes. In our previous studies, the generation of an antiparental response using the murine MHC class I mola deletion in the E3 region, and a mouse MHC class I molecule expression plasmid, pAd-RSV-K b , or a human ecule, H2-K s was observed in vivo. 20 Possibly, the use of a different gene transfer vector (adenovirus) or a different p21 expression plasmid, pAd-p21, respectively. 21, 22 The sequence in the E1A and E1B region is deleted in these MHC haplotype was responsible for this effect. Alternatively, the different tumor cell line, Renca, in the context recombinant adenoviral vectors, impairing their ability to replicate and transform nonpermitting cells. The pAdof a different mouse genetic background, may not have been sufficiently immunogenic to allow induction of the RSV-K b plasmid was prepared by introducing the NdeIBamHI fragment of an H-2K b expression plasmid, pRSVantitumor immune response in vivo. The CTL analysis demonstrated no activity against parental Renca cells or K b into the BglII site of pAd-BglII. 22 The pAd-p21 plasmid was constructed using the NruI-DraIII fragment of a p21 Renca-K b cells in the group treated with ADV-p21 alone. This result is consistent with our previous findings that expression plasmid, pRc/CMV/p21 (25), as well. The recombinant adenoviruses were purified as described expression of the p21 gene product does not lead to the recognition of tumor-specific antigens on Renca cells by previously. 22 the host, but promotes the arrest of cell cycle progression and the induction of terminal differentiation of tumors Flow cytometry analysis Renca cells were infected with either ADV-⌬E1 or ADVby the inhibition of cyclin-dependent kinase activity. 21 Recently, combination gene transfer has been exam-K b at an MOI of 200, as described previously. 22 One day after infection, cells were trypsinized and suspended in ined using other genes for its ability to enhance tumor regression. 23, 24 In one study, a combination of a prodrug DMEM supplemented with 10% FCS. Cells were incubated at 37°C with 5% CO 2 for 1 h to allow the reconverting enzyme, herpes simplex virus thymidine kinase, and a cytokine gene, IL-2 23, 24 was examined. In expression of the H-2K b molecule on the cell surface. Cells were then incubated with murine anti-H-K b antianother case, a combination of cytokine genes, tumor necrosis factor-alpha (TNF␣), and interferon-gamma body (Pharmingen, San Diego, CA, USA) as a first antibody at 4°C for 30 min followed by incubation with FITC-(IFN␥), or IL-2 and IFN␥ has been explored. 24 In both cases, combination therapies conferred a longer survival conjugated anti-mouse IgG (Sigma, St Louis, MO, USA) using the same conditions. Cell surface expression of the rate and a lower rate of tumor growth than either treatment alone. In this report, we used the combination of H-2K b molecule was analyzed by flow cytometry (FACScan; Becton Dickinson, San Jose, CA, USA). H-2K b and p21 genes. Although the combination therapy of both genes can augment the rate of tumor rejection when compared with either treatment alone, our findings
In vivo treatment of tumors Five-week-old BALB/c mice (Charles River Lab, Wilin in vivo studies suggest that the set of H-2K b and p21 genes renders an additive effect rather than a synergistic mington, MA, USA) were pre-immunized twice by intraperitoneal (i.p.) injection with irradiated (25 Gy) spleen effect for tumor rejection. One explanation for this observation is that both genes were subcloned into indecells from C57BL6 mice. Following the second preimmunization, mice were inoculated subcutaneously pendent adenoviruses. Although expression of both gene products within the same vector may enhance this effect with 1 × 10 6 Renca cells on the right flank. After the tumor was established, recombinant adenoviral vectors further, the present approach facilitates the analysis of different genes for combination treatment. Such protocols (2 × 10 8 p.f.u. in 50 l of PBS) were injected directly into tumor tissues. 20, 21 Infusions of the adenoviral vectors for combination gene transfer may advance efforts to develop improved treatments for malignancy. In were performed once per day for 5 days during the first week and twice at 2-day intervals during the second addition, the ability to use such gene transfer approaches together with conventional pharmacologic or immunoweek. therapeutic approaches may potentiate the effects of each treatment modality and increase the possibility of eradCytolytic T lymphocyte (CTL) assay Splenic lymphocytes were prepared and two mice conicating minimal residual disease in malignancy.
taining an average-sized tumor were killed from each group. Cells were sensitized in vitro with Renca-K b cells,
Materials and methods
a stable transfectant of Renca cells containing the expression vector encoding the murine H-2K b gene. SensCell culture A mouse renal carcinoma cell line, Renca (H-2K d , 15 ), was itization was continued for 5 days with 20 U/ml human recombinant IL-2. CTL assays were performed using maintained in Dulbecco's modified Eagle's medium
